A Double-Blind, Randomized, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of V950 Formulated on Aluminum-Containing Adjuvant With or Without ISCOMATRIX™ in Patients With Alzheimer Disease is a PHASE1 clinical asset sponsored by Merck Sharp & Dohme LLC in Alzheimer Disease. SEO and diligence focus: V950, ISCOMATRIX™, Placebo to V950, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.